Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is a clinical-stage biotechnology company with promising product candidates targeting autoimmune and inflammatory diseases. Analysts believe that the dual anti-IL-17 and anti-BAFF activity of Tibulizumab could provide greater benefits than current therapies, and that the company has taken steps to minimize variability between trial sites. Tibulizumab has shown potential for strong sales in Hidradenitis Suppurativa, a condition with a significant unmet need, and is expected to be priced competitively with other biologics in the space. The company has a strong cash position and a seasoned management team, with potential for significant future milestones and royalties from partnerships. However, risks include potential intellectual property challenges and stock price volatility due to market dynamics.

Bears say

Zura Bio is facing significant challenges in the development and commercialization of their novel medicines for autoimmune and inflammatory diseases. Despite promising assets in their pipeline, the company faces risks related to funding and competition, as well as uncertainties in the understanding and treatment of these complex diseases. Their expected results in late 2026 may be delayed or not meet expectations, resulting in a negative outlook for the stock.

ZURA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.